Stock Alert: InflaRx N.V Continues To Trend Higher

Shares of clinical-stage biopharmaceutical company InflaRx N.V. (IFRX) were up $0.62 or 7.77% Thursday before closing at $8.60. It has traded in the range of $2.17- $42.99 in the last 52-weeks.

Yesterday, InflaRx has reported first-quarter results and updated about the ongoing clinical studies.

The company's lead product candidate is IFX-1, a monoclonal anti-C5a antibody, designed to inhibit the biological activity of C5a.

A phase II study of IFX-1 in COVID-19 patients with severely progressed pneumonia is underway. Preclinical data showed that IFX-1 exhibited the ability to control the inflammatory response-related tissue and organ damage via a selective blockade of C5a in the adaptive, randomized, controlled trial.

In March, the company had received positive data from two initial Covid-19 patients with severe pneumonia who were treated with BDB-001, an anti-C5a antibody produced by the company's licensee Beijing Defengrei Biotechnology in China.

IFX-1 is in development to treat inflammatory conditions such as hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum. IFX-1, in combination with Merck's anti-PD-1 therapy, Keytruda is being evaluated in patients with an undisclosed tumor type.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT